Last reviewed · How we verify
TCG
TCG works by inhibiting the activity of certain enzymes in the body.
TCG works by inhibiting the activity of certain enzymes in the body. Used for Hypertriglyceridemia, Mixed dyslipidemia.
At a glance
| Generic name | TCG |
|---|---|
| Also known as | Paclitaxel/Carboplatin/Gemcitabine |
| Sponsor | AGO Study Group |
| Drug class | Fibrates |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
TCG is a medication that specifically targets and inhibits the activity of certain enzymes, which are involved in the breakdown of certain fatty acids. This mechanism of action leads to a decrease in the production of very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol in the liver, resulting in a reduction of triglyceride levels in the blood.
Approved indications
- Hypertriglyceridemia
- Mixed dyslipidemia
Common side effects
- Abdominal pain
- Nausea
- Diarrhea
Key clinical trials
- Safety and Immunogenicity Study of Na-GST-1 With or Without CpG (PHASE1)
- Opioid-Free Anesthetic for Tonsillectomy (PHASE4)
- Antiplatelet Therapies in Patients With Depression and Coronary Disease
- Pilates Method in People With HAM/TSP (NA)
- Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TCG CI brief — competitive landscape report
- TCG updates RSS · CI watch RSS
- AGO Study Group portfolio CI